Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3a Observer-blind, Randomized, Placebo-controlled, Multi-country Study to Evaluate the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors

NCT07872046 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07872046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07872046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3a Observer-blind, Randomized, Placebo-controlled, Multi-country Study to Evaluate the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
November 25, 2032
Enrollment
16,390 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease